Ovarian Cancer Clinical Trials

Showing 461-480 of 902 trials

Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer

NCT01809379

This trial aims to assess efficacy and safety of an intraperitoneal, aerosol, high-pressure chemotherapy in women with recurrent ovarian cancer

Recurrent Ovarian Cancer

Ruhr University of Bochum69 participantsStarted Feb 2013

Bochum, North Rhine-Westphalia, Germany

COMPLETEDPhase 1

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

NCT03075462

Fluzoparib is an oral potent, selective poly-ADP ribose polymerase-1 (PARP-1) and PARP-2 inhibitor; Apatinib is an oral selective vascular endothelial growth factor receptor (VEGFR) inhibitor. This open-label, dose finding phase I trial studies the tolerability and the best dose of fluzoparib in combination with apatinib and to see how well these two drugs work together in the treatment of patients with recurrent ovarian cancer or triple negative breast cancer. The safety and efficacy of fluzoparib in combination with apatinib will be explored. Both dose escalation and dose expansion parts are included in this study.

Ovarian CancerTriple Negative Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.98 participantsStarted Mar 2017

Beijing, Beijing Municipality, China

WITHDRAWNPhase 1

OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer

NCT04941378

The primary objective of the study is to compare the performance of different camera imaging systems in assessing the positive predictive values and sensitivity of OTL38 to detect folate positive ovarian cancer cancers using the gold standard of pathologic review.

Ovarian Cancer

Abramson Cancer Center at Penn MedicineStarted May 2022

Philadelphia, Pennsylvania, United States

Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer

Related Searches

Vitamin D and Pre Cachexia and Cancer Cachexia in Epithelial Ovarian Cancer

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Expanded Access to Veliparib

A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi

Integrated Care Pathway in Oncology (PASSION)

Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer

A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies

Niraparib Plus Anlotinib for Recurrent Ovarian Cancer

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial

Chromosomal Instability in Ovarian Cancer

Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)